litlas
Log inCreate account

Neil P. Shah

Active 1985–2024

84
Papers
26,683
Citations
67
h-index
83
i10-index

Citations

Citations per year for Neil P. Shah1979: 6 citations1985: 3 citations1986: 17 citations1987: 11 citations1988: 8 citations1989: 4 citations1990: 4 citations1991: 9 citations1992: 8 citations1993: 5 citations1994: 2 citations1995: 7 citations1996: 15 citations1997: 14 citations1998: 26 citations1999: 23 citations2000: 14 citations2001: 15 citations2002: 23 citations2003: 58 citations2004: 82 citations2005: 158 citations2006: 250 citations2007: 370 citations2008: 339 citations2009: 323 citations2010: 253 citations2011: 228 citations2012: 228 citations2013: 223 citations2014: 267 citations2015: 292 citations2016: 271 citations2017: 198 citations2018: 200 citations2019: 695 citations2020: 826 citations2021: 619 citations2022: 497 citations2023: 299 citations2024: 586 citations2025: 208 citations2026: 9 citations1980–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,506 citing papers, 32.3% of this breakdownGermany: 554 citing papers, 7.1% of this breakdownUnited Kingdom: 514 citing papers, 6.6% of this breakdownChina: 490 citing papers, 6.3% of this breakdownItaly: 458 citing papers, 5.9% of this breakdownFrance: 374 citing papers, 4.8% of this breakdownAustralia: 234 citing papers, 3% of this breakdownJapan: 230 citing papers, 3% of this breakdownCanada: 211 citing papers, 2.7% of this breakdownSwitzerland: 182 citing papers, 2.3% of this breakdownSpain: 176 citing papers, 2.3% of this breakdownNetherlands: 170 citing papers, 2.2% of this breakdown
0%32.3%Other 21.5%

Institutions

Fields

  • Medicine67.8%
  • Biochemistry, Genetics and Molecular Biology19.8%
  • Immunology and Microbiology7.5%
  • Computer Science1.9%
  • Chemistry0.9%
  • Mathematics0.7%
  • Other1.4%

Topics

  • Chronic Myeloid Leukemia Treatments14.9%
  • Chronic Lymphocytic Leukemia Research7.6%
  • Acute Myeloid Leukemia Research6.5%
  • Eosinophilic Disorders and Syndromes5.4%
  • Acute Lymphoblastic Leukemia research3.8%
  • Protein Degradation and Inhibitors2.8%
  • Other59%

Coauthors

All papers

Open in search
  1. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Authors: Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Siu‐Fun Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah, Hagop M. Kantarjian - New England Journal of Medicine 2013 cited by 1,124

  2. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Authors: Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian - Blood 2018 cited by 583

  3. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Authors: Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian, Michele Baccarani, Jiřı́ Mayer, Concepción Boqué, Neil P. Shah, Charles Chuah, Luís Casanova, Brigid Bradley-Garelik, George Manos, Andreas Hochhaus - Journal of Clinical Oncology 2016 cited by 946

  4. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

    Authors: Christine M. McMahon, Timothy T. Ferng, Jonathan Canaani, Eunice S. Wang, Jennifer J.D. Morrissette, Dennis J. Eastburn, Maurizio Pellegrino, Robert Durruthy-Durruthy, Christopher D. Watt, Saurabh Asthana, Elisabeth A. Lasater, RosaAnna DeFilippis, Cheryl A.C. Peretz, Lisa H.F. McGary, Safoora Deihimi, Aaron C. Logan, Selina M. Luger, Neil P. Shah, Martin Carroll, Catherine C. Smith, Alexander E. Perl - Cancer Discovery 2019 cited by 437

  5. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

    Authors: Neil P. Shah, Chris Tran, Francis Y. Lee, Ping Chen, Derek Norris, Charles L. Sawyers - Science 2004 cited by 1,810

  6. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Authors: Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus, Jörge E. Cortes, Sandip Shah, Manuel Ayala, Beatriz Moiraghi, Zhixiang Shen, Jiřı́ Mayer, Ricardo Pasqüini, Hirohisa Nakamae, Françoise Huguet, Concepción Boqué, Charles Chuah, Eric Bleickardt, M. Brigid Bradley‐Garelik, Chao Zhu, Ted P. Szatrowski, Д. А. Шапиро, Michele Baccarani - New England Journal of Medicine 2010 cited by 1,582

  7. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

    Authors: Catherine C. Smith, Qi Wang, Chen-Shan Chin, Sara Salerno, Lauren E. Damon, Mark J. Levis, Alexander E. Perl, Kevin Travers, Susana Wang, Jeremy P. Hunt, Patrick P. Zarrinkar, Eric E. Schadt, Andrew Kasarskis, John Kuriyan, Neil P. Shah - Nature 2012 cited by 750

  8. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Authors: Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, Nicholas J. Donato, John Nicoll, Ron Paquette, Jörge E. Cortes, Susan O’Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath R. Iyer, Tai‐Tsang Chen, Fei Huang, Arthur P. DeCillis, Charles L. Sawyers - New England Journal of Medicine 2006 cited by 1,772

  9. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

    Authors: Neil P. Shah, Ravi Bhatia, Jessica K. Altman, Maria L. Amaya, Kebede H. Begna, Ellin Berman, Onyee Chan, Joan Clements, Robert H. Collins, Peter Curtin, Daniel J. DeAngelo, Michael W. Drazer, Lori J. Maness, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Vivian G. Oehler, Keith W. Pratz, Iskra Pusic, Michal G. Rose, William Shomali, B. Douglas Smith, Michael Styler, Moshe Talpaz, Tiffany Tanaka, Srinivas K. Tantravahi, James E. Thompson, Steven Tsai, Jennifer E. Vaughn, Jeanna Welborn, David T. Yang, Hema Sundar, Kristina M. Gregory - Journal of the National Comprehensive Cancer Network 2024 cited by 118

  10. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

    Authors: Raghuveer Singh Mali, Qi Zhang, RosaAnna DeFilippis, Antonio Cavazos, Vinitha M. Kuruvilla, Jayant Raman, Vidhi Mody, Edna F. Choo, Monique Dail, Neil P. Shah, Marina Konopleva, Deepak Sampath, Elisabeth A. Lasater - Haematologica 2020 cited by 140

  11. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Authors: Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah, Dale L. Bixby, Michael J. Mauro, Ian W. Flinn, Thomas O’Hare, Simin Hu, Narayana I. Narasimhan, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Brian Druker, Michael W. Deininger, Moshe Talpaz - New England Journal of Medicine 2012 cited by 770

  12. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

    Authors: Pietro Ciceri, Susanne Müller, Alison O’Mahony, O. Fedorov, P. Filippakopoulos, Jeremy P. Hunt, Elisabeth A. Lasater, Gabriel Pallares, S. Picaud, Christopher Wells, Sarah Martin, Lisa Wodicka, Neil P. Shah, Daniel K. Treiber, Stefan Knapp - Nature Chemical Biology 2014 cited by 350

  13. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

    Authors: Jörge E. Cortes, Alexander E. Perl, Hartmut Döhner, Hagop M. Kantarjian, Giovanni Martinelli, Tibor Kovacsovics, Philippe Rousselot, Björn Steffen, Hervé Dombret, Elihu H. Estey, Stephen A. Strickland, Jessica K. Altman, Claudia D. Baldus, Alan K. Burnett, Alwin Krämer, Nigel H. Russell, Neil P. Shah, Catherine C. Smith, Eunice S. Wang, Norbert Ifrah, Guy Gammon, Denise Trone, Deborah Lazzaretto, Mark J. Levis - The Lancet Oncology 2018 cited by 264

  14. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

    Authors: Jeffrey H. Lipton, Charles Chuah, Agnès Guerci‐Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Étienne, Franck E. Nicolini, Philipp le Coutre, Richard E Clark, Leif Stenke, David Andorsky, Vivian G. Oehler, Stephanie Lustgarten, Victor M. Rivera, Timothy Piers Clackson, Frank G. Haluska, Michele Baccarani, Jörge E. Cortes, François Guilhot, Andreas Hochhaus, Timothy P. Hughes, Hagop M. Kantarjian, Neil P. Shah, Moshe Talpaz, Michael Deininger - The Lancet Oncology 2016 cited by 259

  15. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

    Authors: Neil P. Shah, John Nicoll, Bhushan Nagar, M. Gorre, Ronald Paquette, John Kuriyan, Charles L. Sawyers - Cancer Cell 2002 cited by 1,625

  16. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Authors: Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes, Michele Baccarani, M B Agarwal, María Soledad Undurraga, Jianxiang Wang, Juan Julio Kassack Ipiña, Dong‐Wook Kim, Michinori Ogura, Carolina Pavlovsky, Christian Junghanß, Jorge Milone, Franck E. Nicolini, Tadeusz Robak, Jan Van Droogenbroeck, Edo Vellenga, M. Brigid Bradley‐Garelik, Chao Zhu, Andreas Hochhaus - Blood 2011 cited by 605

  17. Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

    Authors: Kathryn G. Roberts, Ryan D. Morin, Jinghui Zhang, Martin Hirst, Yongjun Zhao, Xiaoping Su, Shann-Ching Chen, Debbie Payne-Turner, Michelle L. Churchman, Richard C. Harvey, Xiang Chen, Corynn Kasap, Chunhua Yan, Jared Becksfort, Richard P. Finney, David T. Teachey, Shannon L. Maude, Kane Tse, Richard A. Moore, Steven J.M. Jones, Karen Mungall, İnanç Birol, Michael N. Edmonson, Ying Hu, Kenneth Buetow, I‐Ming Chen, William L. Carroll, Lei Wei, Jing Ma, Maria Kleppe, Ross L. Levine, Guillermo Garcia‐Manero, Eric Larsen, Neil P. Shah, Meenakshi Devidas, Gregory H. Reaman, Malcolm A. Smith, Steven W. Paugh, William E. Evans, Stephan A. Grupp, Sima Jeha, Ching‐Hon Pui, Daniela S. Gerhard, J R Downing, Cheryl L. Willman, Mignon L. Loh, Stephen P. Hunger, Marco A. Marra, Charles G. Mullighan - Cancer Cell 2012 cited by 718

  18. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

    Authors: Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori J. Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian G. Oehler, Arnel Pallera, Mrinal M. Patnaik, Keith W. Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra Sweet, Moshe Talpaz, James E. Thompson, David T. Yang, Kristina M. Gregory, Hema Sundar - Journal of the National Comprehensive Cancer Network 2020 cited by 265

  19. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia

    Authors: Ehab Atallah, Charles A. Schiffer, Jerald P. Radich, Kevin P. Weinfurt, Mei-Jie Zhang, Javier Pinilla‐Ibarz, Vamsi Kota, Richard A. Larson, Joseph O. Moore, Michael J. Mauro, Michael W. Deininger, James E. Thompson, Vivian G. Oehler, Martha Wadleigh, Neil P. Shah, Ellen K. Ritchie, Richard T. Silver, Jörge E. Cortes, Li Lin, Alexis Visotcky, Arielle Baim, Jill Harrell, Bret Helton, Mary M. Horowitz, Kathryn E. Flynn - JAMA Oncology 2020 cited by 105

  20. Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia

    Authors: Hagop M. Kantarjian, Elias Jabbour, Michael W. Deininger, Elisabetta Abruzzese, Jane F. Apperley, Jörge E. Cortes, Charles Chuah, Daniel J. DeAngelo, John F. DiPersio, Andreas Hochhaus, Jeffrey H. Lipton, Franck E. Nicolini, Javier Pinilla‐Ibarz, Delphine Réa, Gianantonio Rosti, Philippe Rousselot, Neil P. Shah, Moshe Talpaz, Shouryadeep Srivastava, Xiaowei Ren, Michael J. Mauro - American Journal of Hematology 2022 cited by 45

  21. Crenolanib is a selective type I pan-FLT3 inhibitor

    Authors: Catherine C. Smith, Elisabeth A. Lasater, Kimberly C. Lin, Qi Wang, Melissa Q. McCreery, Whitney Stewart, Lauren E. Damon, Alexander E. Perl, Grace R. Jeschke, Mayumi Sugita, Martin Carroll, Scott C. Kogan, John Kuriyan, Neil P. Shah - National Academy of Sciences, Proceedings of the National Academy of Sciences 2014 cited by 210

  22. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

    Authors: Catherine C. Smith, Kevin Lin, Adrian Stecuła, Andrej Šali, Neil P. Shah - Leukemia 2015 cited by 206

  23. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

    Authors: Simona Soverini, Susan Branford, Franck E. Nicolini, Moshe Talpaz, Michael W. Deininger, Giovanni Martinelli, Martin C. Müller, Jerald P. Radich, Neil P. Shah - Leukemia Research 2013 cited by 193

  24. Ins and Outs of Kinase DFG Motifs

    Authors: Daniel K. Treiber, Neil P. Shah - Chemistry & Biology 2013 cited by 164